ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1103

Brain Derived Neurotrophic Factor Is Elevated In Patients With Rheumatoid Arthritis and Secondary Fibromyalgia

Able Lawrence, Venkatesh Pai, Rajni Srivastava, Vikas Agarwal, Ramnath Misra and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: depression, disability and quality of life, Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Secondary Fibromyalgia is seen in 15% of patients with rheumatoid arthritis (RA). Neurotrophins are elevated in patients with active arthritis and BDNF is elevated in primary Fibromyalgia. We did a cross sectional and longitudinal study to evaluate the association of FMS and tender points with RA disease activity, depression and neurotrophins in patients with RA. 

Methods: Female patients of RA with and without Fibromyalgia (ACR 1990 criteria) were recruited.  RA disease activity was assessed by DAS28-3v, depression by BPHQ and health related quality of life by WHO HRQoL Bref. Plasma neurotrophins NGF, BDNF, NT3 and NT4 were tested by ELISA. Longitudinal analysis was done using linear mixed model analysis using a fixed effects model adjusting for covariates. 

Results: We recruited 40 female patients with RA and secondary FMS and 43 with RA and no FMS. Mean age was 42.2 yrs (20- 66), duration of RA 5.9 yrs (0.6- 22) and mean age of onset was 36.4 yrs (16-59). Of these 38 patients had two or more visits and 14 had 3 visits.  At baseline, patients with FMS had more depression by BPHQ (12.8 vs 8) and tender points (14.8 vs 3.4) compared to those without FMS while HAQ, DAS28, age and ESR were similar.

FMS status, DAS28-3v, swollen joints, and HAQ-DI were independent predictors of fibromyalgia tender points with standardized regression coefficients of 0.75 (p<0.001), 0.13 (p<0.05), 0.16 ( p<0.005) and 0.14 (p<0.05) respectively. Quality of life was significantly decreased in physical, psychological, social and environmental domains in patients with fibromyalgia even after controlling for disease activity, HAQ-DI and depression with mean differences of 5.71 (p<0.001), 6.06 (p<0.001), 9.19 (p<0.001) and 2.99 (p<0.001) respectively.

At baseline patients with RA and FMS had higher mean  BDNF (49.8 +/- 18.2 ng/ml) compared those without FMS (41.5 +/- 17.5; p<0.05). On multivariate analysis, the estimated means were  54.5 ng/ml (SE 2.1) and 43.5 ng/ml(SE 2.3) respectively with p<0.001 and. NGF, NT3 and NT4 were detectable in 3, 14 and 4 patients at baseline.  

Conclusion: Rheumatoid arthritis disease activity and disability influences the severity of fibromyalgia. BDNF is elevated in secondary FMS associated with RA. Elevated BDNF may be contributing to FMS in RA patients.


Disclosure:

A. Lawrence,
None;

V. Pai,
None;

R. Srivastava,
None;

V. Agarwal,
None;

R. Misra,
None;

A. Aggarwal,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/brain-derived-neurotrophic-factor-is-elevated-in-patients-with-rheumatoid-arthritis-and-secondary-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology